Q-omics provides the consensus-scored ISCA1P2 profile across patient tissues and cancer cell-line models. ISCA1P2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ISCA1P2 is differentially expressed in 1, with the highest sampling consensus in COAD. Additionally, ISCA1P2 RNA expression shows 5,978 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, COAD, and STAD as cancer lineages where ISCA1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ISCA1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ISCA1P2 survival associations across molecular data types. ISCA1P2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ISCA1P2 RNA expression–survival associations across cancer types. High ISCA1P2 expression shows unfavorable associations in BLCA, LUAD, THYM, COAD, DLBC and THCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ISCA1P2 RNA expression.
This table summarizes ISCA1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ISCA1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ISCA1P2 shows lower tumor expression in COAD. The COAD box plot shows higher ISCA1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p = .031).
This table shows molecular features associated with ISCA1P2 in patient tissues and cancer cell lines. In patient samples, ISCA1P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
